[Intravitreal and intracameral bevacizumab in neovascular glaucoma: an interventional case series]

ABSTRACT

To evaluate the effects of intravitreal and intracameral injection of bevacizumab in patients with neovascular glaucoma [NVG]. This interventional case series was conducted on 40 eyes of 40 patients with neovascular glaucoma. Data included the extent of iris [NVI] and angle neovascularization [NVA], peripheral anterior synechia [PAS], and intraocular pressure [IOP]. Following standard NVG treatment, 1.5 and 1 mg of Bevacizumab were injected intravitreally and intracamerally, respectively. Six weeks after injection, the same procedure was repeated. Intraocular pressure decreased significantly from 40.15 +/- 18.33 to 29.27 +/- 15.07 mmHg [P<0.001]. NVI and NVA were eliminated in 97.5% and 100% of patients, respectively. No significant change was seen in best corrected visual acuity [BCVA]. After the injection, hyphema occurred only in one eye. Intravitreal and intracameral injection of bevacizumab is an effective complementary treatment for reducing NVI and NVA and hence IOP in NVG